🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

265 results for “LG” Clear

  1. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Epileptic seizures

    phase 1 other active

    1 trial

  2. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  3. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects und

    Lacuna Pharma Pty Ltd

    Epilepsy

    phase 1 other active

    1 trial

  4. Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen

    Lacuna Pharma Pty Ltd

    Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

    phase 1 small molecule active

    1 trial

  5. CC-486

    Celgene Europe Limited

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  6. Clascoterone Cream 1%

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acne Vulgaris

    phase 1 small molecule completed

    1 trial

  7. Computer algorithm for ATTR

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis

    phase 1 other terminated

    1 trial

  8. FMX101 vehicle

    VYNE Therapeutics

    Acne Vulgaris

    phase 1 small molecule completed

    1 trial

  9. Filgotinib

    Lakefront Biotherapeutics NV

    Bioavailability

    phase 1 small molecule completed

    1 trial

  10. Filgrastim

    Rocket Pharmaceuticals B.V.

    Fanconi Anemia

    phase 1 mab terminated

    1 trial

  11. GTX-101

    Grace Therapeutics

    Postherpetic Neuralgia

    phase 1 small molecule active

    1 trial

  12. HD204

    Prestige Biopharma Belgium

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. LGD-6972

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    2 trials

  14. LGD-6972 Solution

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus (T2DM)

    phase 1 small molecule completed

    1 trial

  15. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  16. LGH447

    Novartis Pharmaceuticals

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  17. Lipegfilgrastim

    Teva Pharma GmbH

    Ewing Family of Tumors, Rhabdomyosarcoma

    phase 1 small molecule completed

    1 trial

  18. MARVEL algorithm

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrioventricular Conduction Block

    phase 1 other completed

    1 trial

  19. METRONIDAZOLE, MOLGRAMOSTIM, Saline Solution Basi 9 mg/ml solution for infusion, FOSFOMYCIN

    Lacuna Pharma Pty Ltd

    peritonitis

    phase 1 small molecule active

    1 trial

  20. Pegfilgrastim

    Biotech Pharmaceutical Co.,

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  21. Pevifoscorvir Sodium (ALG-000184)

    Aligos Therapeutics

    Chronic Hepaititis B Infections

    phase 1 small molecule active

    1 trial

  22. Pevifoscorvir Sodium (ALG-000184)

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 1 small molecule active

    1 trial

  23. Safety and tolerability of medicated chewing gum with sodium alginate, calcium carbonate and sodium bicarbonate.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  24. Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources